Azacitidine

Drug Profile

Azacitidine

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; Vidaza

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Australasian Leukaemia & Lymphoma Group; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Nippon Shinyaku; Pfizer; University of Colorado at Denver; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Solid tumours
  • Phase I Lymphoma; Multiple myeloma

Most Recent Events

  • 13 Jun 2017 Columbia University plans a phase I/II trial for T-cell lymphoma (Combination therapy) in USA (NCT03161223)
  • 07 Jun 2017 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme plan a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (NCT03182894)
  • 19 May 2017 Celgene completes a phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Maintenance therapy) in the United Kingdom and USA (PO) (NCT01835587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top